Table 2 Outcomes of clinical trials of CAR T cells targeting T cell malignancies

Patients

1

10

20

Conditioning regimen

Fludarabine (150 mg/ m²), cyclophosphamide (120 mg/kg) and alemtuzumab (1 mg/kg)

Fludarabine (25–30 mg/m²/d), cyclophosphamide (300 mg/m²/d) and etoposide (100 mg/m²/d) on Day -6 to Day -3

ORR/CR

1/1 MRD negative on day 28

8/10 (80%) CR on day 28

18/20 (90%) ORR at 3 months

PFS

4/6(66.7%) 315-day PFS

62.3% 1-year PFS

OS

60% 1-year OS

GVHD

0/1

8/20 (40%) grade 1–2 GvHD

CRS/ICANS

1/1 grade 2 CRS 1/1 grade 1 ICANS

9/10 (90%) grade 1 CRS, 1/10 (10%) grade 3CRS

2/20 (10%) grade 3 or higher CRS

Clinical trial number

ISRCTN15323014

NCT04620655

NCT04689659

References

[4]

[5]

[6]